Shire PLC (NASDAQ:SHPG) – SunTrust Banks boosted their Q2 2017 earnings per share (EPS) estimates for Shire PLC in a report issued on Wednesday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will post earnings of $3.62 per share for the quarter, up from their prior estimate of $3.59.

Shire PLC (NASDAQ:SHPG) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.53 by $0.20. The business had revenue of $3.75 billion during the quarter. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The business’s quarterly revenue was up 54.2% on a year-over-year basis. During the same period last year, the business earned $3.38 EPS.

WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/09/q2-2017-eps-estimates-for-shire-plc-lifted-by-analyst-nasdaqshpg.html.

A number of other equities analysts have also recently issued reports on SHPG. Cantor Fitzgerald set a $222.00 target price on Shire PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a report on Tuesday. Jefferies Group LLC reiterated a “buy” rating and set a $216.00 target price (down previously from $239.00) on shares of Shire PLC in a report on Friday, June 9th. BidaskClub cut Shire PLC from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $210.00 target price on shares of Shire PLC in a report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $223.18.

Shares of Shire PLC (NASDAQ SHPG) opened at 156.86 on Monday. The firm has a market cap of $46.72 billion, a PE ratio of 160.88 and a beta of 1.60. The stock has a 50 day moving average price of $166.27 and a 200 day moving average price of $172.96. Shire PLC has a 12 month low of $155.06 and a 12 month high of $209.22.

A number of large investors have recently modified their holdings of the stock. Dumont & Blake Investment Advisors LLC increased its position in Shire PLC by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 2,594 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 7 shares during the period. Inspirion Wealth Advisors LLC increased its position in Shire PLC by 0.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 8 shares during the period. Level Four Advisory Services LLC increased its position in Shire PLC by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 13 shares during the period. Thompson Davis & CO. Inc. increased its position in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 19 shares during the period. Finally, Baldwin Investment Management LLC increased its position in Shire PLC by 1.4% in the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 23 shares during the period. Institutional investors and hedge funds own 21.04% of the company’s stock.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Earnings History and Estimates for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.